A new editorial paper was published in Oncoscience (Volume 10) on June 28, 2023, entitled, "Adenoid cystic carcinoma of the head and neck – treatment strategies of a highly malignant tumor with ...

Servier today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to ...

The malignancies of Bartholin's gland, although exceedingly rare, represent a diagnostic and therapeutic challenge for clinicians. Bartholin’s gland carcinoma encompasses several histological subtypes ...

BUFFALO, NY – December 4, 2024 – A new editorial was published in Oncotarget’s Volume 15 on November 22, 2024, entitled “B7-H4: A potential therapeutic target in adenoid cystic carcinoma.” Researchers ...

Adenoid cystic carcinoma (ACC) of the breast is a rare and distinctive form of breast cancer, accounting for less than 0.1% of all breast malignancies. Despite its triple‐negative immunophenotype, ...

Predictive factors in advanced head and neck cancer treated by radio-chemotherapy and hypoxia modification No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the ...

The impact of radiotherapy, in addition to chemotherapy, on overall survival in the initial management of patients with newly diagnosed metastatic head and neck squamous cell carcinoma. This is an ...

“Proton therapy [...] seems to have decisive advantages with regard to the long-term survival of [adenoid cystic carcinoma] [...]” In general, tumors originating from the minor salivary glands often ...